- Poster presentation
- Open Access
Tafamidis reduces disease progression in patients with transthyretin familial amyloid polyneuropathy: supportive post-hoc analyses of a pivotal trial
© Keohane et al. 2015
- Published: 2 November 2015
- Pivotal Trial
- Treatment Effect Estimate
- Assigned Treatment
- European Academy
- Repeated Measure Model
Safety and efficacy of once-daily 20 mg tafamidis, a transthyretin (TTR) stabilizer, was evaluated in an 18-month, multicentre, randomized, double-blind, placebo-controlled study in 128 patients with early symptomatic V30M TTR familial amyloid polyneuropathy (TTR-FAP). In the intent-to-treat population, a responder analysis for Neuropathy Impairment Score-Lower Limb (NIS-LL) (co-primary with Norfolk Quality of Life-Diabetic Neuropathy) favoured tafamidis (P=0.07). A pre-specified, key secondary analysis of change from baseline to Month 18 in NIS-LL continuous scores was significant (P=0.04). Placebo-corrected point estimates for 5 pre-specified and validated measures of disease progression also favoured tafamidis and were directionally consistent. Additional post-hoc analyses supporting tafamidis for delaying progression of TTR-FAP are reported here.
Change from baseline in NIS-LL over time was analysed with the addition of the baseline values as a covariate in a repeated measures model. A sensitivity multiple imputation analysis with imputed values based on assigned treatment group was also performed. Additionally, change in NIS-LL+ summated 7 (neurophysiological function composite endpoint) over time was assessed.
When adjusted for baseline NIS-LL disease severity, statistical significance in change from baseline to Month 18 NIS-LL was retained. The magnitude of separation between placebo and tafamidis was consistent across the full range of baseline values (least squares mean difference = 2.7 points; 95% confidence interval [CI]: 0.1, 5.2; P<0.05). Treatment effect estimates from the multiple imputation analysis, although reduced, were similar to those from the analysis of change from baseline to Month 18, and remained significant. With each batch run representing the results combined from 1000 multiply imputed data sets, the difference in NIS-LL change from baseline to Month 18 for tafamidis versus placebo was -2.787 (standard error [SE]: 1.345; 95% CI: -5.423, -0.151; P=0.04) for Batch Run 1; for Batch Run 2, the difference was -2.815 (SE: 1.351; 95% CI: -5.464, -0.166; P=0.04); and for Batch Run 3, the difference was -2.798 (SE: 1.347; 95% CI: -5.438, -0.157; P=0.04). For NIS-LL+ summated 7, at Month 6, the mean change (standard deviation) was 1.8 (4.82) for the tafamidis group and 4.0 (7.12) for the placebo group (P=0.053); while significant differences between treatment groups were observed at Months 12 (1.6 [5.27] vs 7.8 [8.87], P=0.00009) and 18 (3.4 [5.95] vs 8.8 [10.44], P=0.0043).
The beneficial effects of tafamidis in delaying neurological impairment in TTR-FAP are further supported by these post-hoc analyses.
Note: First presented at the 1st Congress of the European Academy of Neurology, Berlin, Germany, June 2015
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.